Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (8): 506-507.
Previous Articles Next Articles
CAI Jun1,2, JI Liwei1,*
Received:2019-09-09
Revised:2019-09-09
Online:2019-08-20
Published:2019-09-09
CLC Number:
CAI Jun, JI Liwei. One Case of Palpitation Induced by Empagliflozin Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 506-507.
Add to citation manager EndNote|Ris|BibTeX
| [1] 王颐婷, 李伟炜, 谢静文, 等. 氨甲环酸注射液致过敏性休克1例[J]. 中国药物警戒, 2018, 15(8):501-502. [2] 翁建平. 钠-葡萄糖共转运蛋白2抑制剂研究新进展[J]. 中国糖尿病杂志, 2016, 8(11):645-648. [3] Zinman B, Wanner C, Lachin J M, et al.Empagliflozin,cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128. [4] Verma S, Mazer C D, Fitchett D, et al.Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME? randomised trial[J]. Diabetologia, 2018, 61(8):1712-1723. [5] Yang X, Li J, Hu D, et al.Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Popula-tion: The China-PAR Project (Prediction for ASCVD Risk in China)[J]. Circulation, 2016, 134(19):1430-1440. [6] Mudaliar S, Alloju S, Henry R R.Can a shift in fuel energetics EMPA-REG OUTCOME study? a unifying hypothesis[J]. Diabetes Care, 2016, 39(7):1115-1122. [7] Ferrannini E, Baldi S, Frascerra S, et al.Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes[J]. Diabetes, 2016, 65(5):1190-1195. [8] Mayr M, Yusuf S, Weir G, et al.Combined metabolomic and proteomic analysis of human atrial fibrillation[J]. J Am Coll Cardiol, 2008, 51(5):585-594. |
| [1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
| [2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
| [3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
| [4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
| [5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
| [6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
| [7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
| [8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
| [9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
| [10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
| [11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
| [12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
| [13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
| [14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
| [15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
